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Objective: The purpose of this preliminary study was to devise a new surgical
procedure for minimally invasive aortic valve implantation with a transluminal
technique.
Methods: The new collapsible heart valve was prepared by mounting a porcine
aortic valve, taken from a freshly slaughtered pig, into a self-expandable nitinol
stent by means of a suture technique. The outer diameter of the valved stent ranged
from 15 to 23 mm, and the length ranged from 21 to 28 mm. Before implantation
in vivo, these valved stents were tested in an in vitro circulatory system. Only in
vitro–tested valved stents with a pressure gradient of less than 7 mm Hg and
regurgitation of I° or less were used for transluminal aortic valve implantation in
vivo. Six of these valved stents were implanted in the descending aorta and 8 in the
ascending aorta of anesthetized pigs. The catheter delivery system (22F) was
extraperitoneally inserted through the left iliac artery or the infrarenal aorta. Meas-
urements for transvalvular gradient, valvular opening and closure, blood-flow char-
acteristics, regurgitation, and macroscopic analysis were performed at baseline and
after the observation period (164  48 minutes).
Results: This preliminary study contained 14 animals. One animal died of ventric-
ular fibrillation. Technical failure occurred in 2 pigs as a result of stent twisting. At
the end of the observation period, the 11 successfully implanted valved stents
demonstrated low transvalvular gradients (mean end-systolic max of 5.4  3.3
mm Hg for the descending aorta group, 5.4  1.2 mm Hg for the supracoronary
group, and 5.4  1.1 mm Hg for the subcoronary group), which did not differ from
their in vitro gradients. Two-dimensional echocardiography demonstrated complete
valvular closure and opening in 5 of 5 cases. Angiography indicated only a
physiologic jet of regurgitation (0°) in 8 animals and mild (I°) regurgitation in 3
animals. Color Doppler ultrasonography indicated no regurgitation in 5 of 5 cases
and minor paravalvular leakage in 1 case.
Conclusion: Aortic valved stents can be successfully implanted without thoracotomy
by using a transluminal catheter technique. Long-term function of the valves
remains to be established.
Aortic valve replacement generally has been accomplished by usinga cardiac surgical procedure, whereas endovascular proceduresfor valve replacement may provide an alternative to cardiac sur-gery. Percutaneous transluminal procedures have substantial ben-efits from the standpoints of health and safety, as well as from thestandpoint of cost. Such endovascular procedures require minimal
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invasion of the human body, and there is considerable
reduction and, in some instances, even elimination of gen-
eral anesthesia and intensive care unit stay.
A number of minimally invasive techniques for replacing
heart valves have been experimentally developed over the
last 10 years. Such techniques have been reported by
Andersen and coworkers,1 who indicated in 1992 that arti-
ficial aortic valves can be implanted in closed-chest animals
by means of a transluminal catheter technique; by Pavcnik
and colleagues,2 who demonstrated in 1992 that a percuta-
neous transcatheter placement of an artificial caged-ball
valve in animals is feasible; by Maozami and coworkers,3
who showed in 1996 that a hemodynamically acceptable
prosthetic aortic valve for transluminal placement is feasi-
ble, whereas an open chest model for implantation was
used; and by Bonhoeffer and coworkers4 in 2000, who
successfully performed a percutaneous pulmonary valve
implantation in 5 sheep. Although the instruments, devices,
and techniques reported are clearly experimental, it appears
that each of them still has one or more problems.
It would be especially advantageous if a defective heart
valve could be removed by means of an endovascular pro-
cedure (ie, through the femoral artery). The procedure is
then carried out percutaneously and transluminally by using
the vascular system to convey appropriate devices to the
aortic anulus to carry out the percutaneous aortic valve
ablation procedure.
We set out to develop a technique for placement of a
biologic valve in the aortic position through a transluminal
approach.5 This report presents our initial experience with
transluminal aortic valve implantation in the circulatory
system of anesthetized pigs after this experimental set up
had been developed in more than 30 pilot studies.
Materials and Methods
Experimental Preparation
Production of valved stents. Eleven of the 14 animals re-
ceived homologous valves. These aortic valves were harvested
from fresh porcine cadavers. Seventy percent ethanol solution was
used for transport. The aortic wall of the harvested valve section
was trimmed to remove extraneous material and to reduce the size
(by D.K.). However, sufficient material had to remain to allow
permanent valve configuration and safe attachment of the aortic
valve to the stent.
Pericardial valves were used in the other 3 animals. Pericar-
dium of the same animals was selected for the creation of valves.
Pericardium was cleaned, prepared, preserved with glutaraldehyde
(0.6%), and finally constructed with an ultra-thin polytetrafluro-
ethylene layer to the exterior for stabilization (by D.K.).
The above-described valves were sutured to the interior of a
stent with 7-0 polypropylene sutures. This radially self-expanding
vascular memory stent (21-28 mm in length and 15-23 mm in
diameter) includes several cylindrical fine-wire sections that are
interconnected into a single tubular structure. The size of the
valved stent correlated with the width of the aorta (as determined
with intra-arterial digital subtraction angiography [IA-DSA]) and
body weight. The wires are made of a soft and highly malleable
alloy consisting of nitinol (Nitinol Devices & Components Inc,
Fremont, Calif). The tubular portion of the trimmed ascending
aorta of the stentless aortic valve spanned the partial axial length
of the nitinol stent (Figure 1). For the anchoring fixation, barbs are
attached to the outside of the stent.
The valved stent was finally cross-linked with a buffered saline
solution containing 0.6% glutaraldehyde for 24 hours at 4°C. After
fixation, it was transferred to a 70% ethanol solution for storage.
Before implantation, the valve stent was immersed multiple times
for 15 minutes and carefully rinsed in physiologic saline solution
to remove the ethanol.
Catheter delivery system. The valved stent is inserted by
means of a self-constructed, flexible, catheter-based (external di-
ameter, 22F) delivery technique (overall length, 90 cm) through
the iliac artery or the infrarenal aorta (Figure 2).
In Vitro Studies
An in vitro circulatory system (hydrodynamic pulsatile-flow test-
ing referring to the ISO norm 5840:1996-11-01) was used for the
evaluation of the valved stents. This system (Figure 3) uses a pump
(Sto¨ckert-HLM, 10-40-00; Sto¨ckert Instruments Inc, Munich, Ger-
many) with an external flow controller (PFC-1) to generate pulsa-
tile flow (maximum, 6.0 L/min). Each stroke ejects 63 to 75 mL of
saline solution into the circuit. The system possesses an open
reservoir and a compliance chamber to simulate the venous and
arterial systems, respectively. In addition, peripheral vascular re-
sistance was adjusted by using a blood-flow regulator to the circuit
to partially impede forward flow. The valve was placed into a soft
silicone tube with the same diameter as the aorta of the pigs used
for the in vivo experiments (15-23 mm). An ultrasonic probe
(Toshiba SSH 140A, 5-MHz transesophageal probe; Toshiba
GmbH, Neuss, Germany) was placed on the outflow tubing to
assess valve function. All data were digitized and recorded with
the IBM-Lab system (IBM Inc, New York, NY).
The unitary tubular structure (Figure 1) was reduced in profile
(foldable biologic valve inside a self-expanding memory stent) and
placed on a catheter delivery system. During artificial circulation,
the self-prepared valved stents were transluminally implanted
through a 24F port into the valve chamber (Figure 3). The posi-
tioning of the valved stents into the valve chamber was enabled by
means of direct view through a transparent silicone tube. The
observation period in vitro lasted for 4 hours.
In Vivo Studies
Animals received humane care, as approved by the Center for
Experimental Animal Research at Freiburg University and in com-
pliance with the “Guide for the Care and Use of Laboratory
Animals” prepared by the Institute of Laboratory Animal Re-
sources, National Research Council, and published by the National
Academy Press, revised 1996.
Pigs of the “German Landrace” weighing 64 to 76 kg were
premedicated and anesthetized, as reported elsewhere.6 Only in
vitro–tested valved stents with a pressure gradient of less than 7
mm Hg and a regurgitation of I° or less were used for transluminal
aortic valve implantation in vivo. First, a paracolic incision and an
extraperitoneal approach toward the infrarenal aorta, aortic bifur-
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cation, or the left iliac artery was prepared. This extraperitoneal
access was chosen because femoral arteries of pigs weighing 65 to
75 kg are only 2.5 to 4.0 mm in diameter.
Second, through the iliac communis artery (n  3), the infra-
renal aorta (n  10), or the iliac external artery (n  1), a
guidewire was retrogradely positioned into the proximal descend-
ing aorta or the left ventricle under continuous fluoroscopy. The
valved stent (21-28 mm in length, Figure 1) was then hand crimped
onto the proximal portion (35 mm in length) of a catheter delivery
system (Figure 2). The diameter of the memory stent was depen-
dent on body weight, and the diameter of the ascending or de-
scending aorta was measured by using IA-DSA. The appropriate
size of the valved stent was chosen from different available stent
diameters, ranging from 15 to 23 mm. Because of the expandable
character of the valved stent, minimal oversizing (1-2 mm) did not
affect optimal valve function. The assembly was front loaded in a
22F long sheath to enable a precise positioning (Figure 2). In case
of deployment into the ascending aorta, the ostia of the coronary
Figure 1. View of the homologous valved segment in a vascular memory stent. Note: The anchoring barbs at the
outside of the valved stent ascertain the desired position after embedding.
Figure 2. Catheter delivery system with guidewire, pusher, and external sheath. Note: The valved stent (21-28 mm
in length) was hand crimped onto the proximal portion (35 mm in length) of a catheter delivery system (into the
proximal capsule between the arrows).
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arteries were identified by means of angiography for correct place-
ment of the valved stents. The valved stent was placed at a secure
distance of several millimeters from the coronary ostia into the
ascending aorta (supra-annular placement) and from the native
aortic valve into the left ventricular outflow tract (subannular
placement).
Third, after loading onto the previously positioned guidewire,
the whole system was advanced and inserted into the iliac artery or
infrarenal aorta through a 24F port. The position of the valved stent
was easily tracked fluoroscopically (highly radiopaque stent ma-
terial) and supported by means of transesophageal echocardiogra-
phy (SSH-140A, Toshiba GmbH). The valved stent was slowly
released (memory stent) by pulling the securing sheath back and
deployed in the ascending (subcoronary or supracoronary position)
or proximal descending (distal to the subclavian artery) aorta. The
duration of deployment was 1.7  1.2 minutes. Through the
self-expanded valved stent, the catheter delivery system was sub-
sequently pulled back and removed, leaving the valve assembly in
the desired position. After deployment of the valved stent, the
observation period of all experimental groups lasted 164  48
minutes (range, 90-240 minutes). Data were obtained for all pa-
rameters at baseline and at the end of the observation period.
Experimental Groups
Over a 2-year period, the in vitro and in vivo experimental model
gradually evolved. After the first successful implantations of a
valved stent in the pilot studies (n  30, for details see “Discus-
sion” section), the present preliminary study was started. The 14
animals fulfilled the following inclusion criteria: First, these
valved stents demonstrated adequate performance in the in vitro
experiments, and second, before implantation of these valved
stents, their catheter delivery system has been successfully tested.
In the descending aorta group the in vitro–controlled homolo-
gous valved stents (21-28 mm in length, n  6) were implanted
into the proximal descending aorta (distal to the subclavian artery).
In the supracoronary group valved stents (n  6, 28 mm of
length) were implanted into the proximal ascending aorta (distal to
the coronary ostia) of the anesthetized pigs.
In the subcoronary group 2 pigs received valved stents into the
left ventricular outflow tract (shortly beyond the native valve),
with a shorter stent of 21 mm in length.
Measurements
Assessment of transvalvular gradient. In vitro, pressure tran-
ducers that were placed on the ventricular and the aortic side of the
valved stent were used to analyze the transvalvular gradient shortly
after implantation and after 4 hours (by D.K.). In vivo, blood
pressure was measured online with two 5F Millar micromanom-
eters placed in the proximal and distal area of the deployed valved
stent.
Evaluation of valvular opening and closure. Two-dimen-
sional ultrasonography in vitro (by D.K.) and 2-dimensional trans-
esophageal echocardiography in vivo (by M.H.) were used to
semiquantitatively grade the valvular opening and closure process
Figure 3. Diagram of the hydrodynamic pulsatile-flow testing used for the in vitro testing of valved stents. The
system enables the adjustment of compliance and resistance.
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(0, total valvular opening and closure; I, partial opening or incom-
plete closure of one or more leaflets; II, lack of movement of one
leaflet; and III, lack of movement of 2 or more leaflets; Figure 4).
Blood-flow characteristics. Color Doppler ultrasonography
was used to examine, in vitro (by D.K.) and in vivo (by M.H.), the
blood-flow supravalvular, intravalvular, and subvalvular charac-
teristics of the valved stent.
Regurgitation and paravalvular leakage. Color Doppler ul-
trasonography in vitro (by D.K.) and in vivo (by M.H.) and
additional angiography in vivo were used to assess any valve
insufficiency (0, no; I, mild; II, moderate; III, severe; and IV,
fulminant regurgitation) and paravalvular leakage (0, none; I, mild;
II, moderate; III, severe; and IV, fulminant leakage).
Mortality and complications. All complications (mechanical
and others) and deaths were identified.
Duration of deployment. The time from pushing the valved
stent out of the cranial catheter capsule (Figure 2) and the total
deployment into the left ventricular outflow tract or aortic lumen
was recorded.
Macroscopic analysis. First, the desired positioning of the
valved stent in situ was controlled (0, optimal positioning; I, 5
mm; II, 5 mm; III, 10 mm from the desired position). Second,
the anchoring of the valved stents was determined in situ (0,
sufficient anchoring; I, minimal shift; II, moderate shift; and III,
twisting of the valved stent). Third, all grafts were explanted.
Fourth, the valved stent was rinsed with distilled water to remove
the blood and was macroscopically inspected. Gross leaflet struc-
ture and integrity were analyzed, referring to the grading of mor-
phologic damage (0, no; I, mild; II, moderate; and III, severe
morphologic damage) and thrombus formation (0, none; I, small;
II, moderate; and III, fulminant thrombus formation).
Statistical Analysis
Paired und unpaired t tests with the Bonferroni correction were
used as appropriate. Values are reported as means  SD. Data
were used from all animals who survived the entire observation
period (n  11). Only data of valved stents that demonstrated
sufficient anchoring (0°-I°) were analyzed.
Results
In Vitro Studies
Assessment of transvalvular gradient. After 4 hours in
the hydrodynamic pulsatile-flow testing, the homologous
valved stents demonstrated a pressure gradient of less than
7 mm Hg (mean end-systolic transvalvular gradient max,
4.5  1.7 mm Hg) and pericardial valved stents (mean
end-systolic max, 5.9  1.4 mm Hg) were revealed. In
addition, different pressure values compared with baseline
were not observed.
Evaluation of valvular opening and closure. Semi-
quantitative assessment of the valvular opening and closure
process demonstrated total valvular opening and closure in
all cases.
Blood-flow characteristics. Color Doppler ultrasonog-
raphy demonstrated systolic laminary blood flow in all cases
(supravalvular, intravalvular, and subvalvular).
Regurgitation and paravalvular leakage. Minimal re-
gurgitation was observed in 3 cases (0°-I°), whereas in 11
cases valve insufficiency was excluded (0°). Paravalvular
leakage occurred in 3 of the cases because of a short
distance between the valved stent and silicone tube caused
by the barbs.
In Vivo Studies
Mortality and complications. One animal died of in-
tractable ventricular fibrillation after repositioning of a
guidewire with its catheter tip in the left ventricle. In addi-
tion, technical failure occurred in 2 pigs (supracoronary
group) as a result of stent twisting (III°) in the ascending
Figure 4. In vivo evaluation of a homologous valved stent in the descending aorta under transesophageal
echocardiography control. Note: There is good visualization of the laminar transvalvular blood flow (left) and the
fully closed leaflets of the new valve (right). 1, Nitinol stent; 2, valve cusp.
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aorta. Therefore the length of the stent was increased from
21 to 28 mm, except in the subcoronary group. Afterward,
no twisting occurred in subsequent animals. Eleven animals
were analyzed after successful implantation. Surgical prep-
aration, advancement of the catheter delivery system, and
deployment of the valved stent were well tolerated in all but
2 animals, one with ventricular tachycardia and one with
reversible ventricular fibrillation associated with placement
into the ascending aorta. Bleeding caused by insertion of the
catheter delivery system into the iliac artery or infrarenal
aorta was controlled easily.
Duration of deployment. The duration of deployment
of the valved stents was 1.7  1.2 minutes on average.
Differences between groups were not revealed.
Assessment of transvalvular gradient. At the end of the
observation period, the valved stents did not reveal signif-
icantly higher transvalvular gradients (mean end-systolic
max: 5.4  3.3 mm Hg for the descending aorta group,
5.4  1.3 mm Hg for the supracoronary group, and 5.5 
1.1 mm Hg for the subcoronary group) compared with their
in vitro gradients.
Evaluation of valvular opening and closure. Two-
dimensional echocardiography demonstrated complete val-
vular closure and opening (0°) in all 5 analyzed cases.
Blood-flow characteristics. Laminar blood flow was
observed in 5 of 5 cases by using color Doppler ultrasonog-
raphy to examine the transvalvular blood flow.
Regurgitation and paravalvular leakage. Angiography
indicated no jet of regurgitation (0°) in 8 and mild (I°)
regurgitation in 3 animals (2 in the supracoronary group and
1 in the subcoronary group). Color Doppler ultrasonography
revealed no regurgitation in 5 of 5 cases. Paravalvular
leakage (observed by means of IA-DSA) occurred in none
of the descending aorta group and in one animal of the
subcoronary and one of the supracoronary group. In con-
trast, color Doppler ultrasonography showed minor paraval-
vular leakage in 1 of 5 cases (descending group).
Macroscopic analysis. Good positioning (0°-I°) of the
valved stent was reached in 8 of 11 cases. Two valved stents
had 5 to 10 mm of distance (II°) and 2 valved stents had
more than 10 mm of distance (III°) from the desired position
in the descending artery (close to the subclavian artery). In
one animal the supracoronary valved stent was implanted 6
to 7 mm (II°) too cranial (disturbing the outflow of the
truncus brachiocephalicus), and in another case it shifted 2
to 3 mm (I°) toward the aortic arch. In the subcoronary
group in one animal the valved stent was implanted 2 to 3
mm too proximal into the left ventricular outflow tract.
Macroscopic findings at autopsy demonstrated that the
anchoring barbs of all stents were sufficiently embedded
into the aortic wall in the descending aorta group (0°). In the
ascending aorta group, in 2 cases the valved stent was
sufficiently anchored in the aortic wall or the left ventricular
outflow tract (0°), whereas 2 of the supracoronary group
were not fully embedded (I°) because of minimal shift in the
lumen. In the subcoronary group, in one animal only the
distal barbs were anchored, whereas the proximal barbs did
not reach the wall of the left ventricular outflow tract
because of the positioning of the stent.
Morphologic damage did not occur in any of the placed
stent assemblies (0°). The valves inside the stents were
completely free of thrombus, except in one case (I°) in the
subcoronary group, which presented a thrombus (2  3
mm) between the stent and the outflow tract. No aortic
dissection, hematoma, or bleeding into the aortic wall was
macroscopically seen in any of the pigs.
Discussion
This study introduces a new construction of a collapsible,
sutureless, bioprosthetic aortic valve integrated into a niti-
nol stent for transluminal application. The ability to reduce
the external wall of the homologous valve allowed us to
reduce the diameter of the stent to a size that allowed
transluminal delivery without interfering with the function
of the valve. We chose this design because it passes through
a relatively small introducer system. The valved stent was
inserted by using a delivery technique through a self-con-
structed, flexible catheter (22F in the proximal portion)
through the infrarenal aorta or iliac artery because the
femoral arteries in pigs are only 2.5 to 4 mm in diameter,
which is in contrast to those of 7 to 9 mm in human subjects.
Although this catheter size required retroperitoneal prepa-
ration and arteriotomy in pigs, it could be performed
through a relatively small incision in the human groin. In the
future, further miniaturization of the compressed valve
could even allow a consistent percutaneous delivery. We
used biologic (homologous and pericardial) valves in this
study, whereas other types of foldable valves may also
prove suitable (eg, the tricuspid polyurethane valve).7 In this
preliminary study we analyzed several features of the newly
designed valved stent.
Mortality and Complications
First, 30 pilot studies served for the development of a
suitable catheter delivery system, an optimal handling of the
material, an anchoring mechanism, and a suitable visualiza-
tion method. These pilot animals had a high complication
and mortality rate (83%) caused by stent twisting, dislodge-
ment, difficulties of advancing the catheter delivery system
(around the aortic arch), vessel perforation (because of
rigidity of the delivery system), and myocardial ischemia
(caused by placing the stent too close to the coronary ostia).
However, after improvement of material and insertion
techniques among the 14 animals of this study group, all but
one survived the procedure and the following observation
period. More secure and easier placement of the aortic valve
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assembly was accomplished after increasing the height of
the stent (except for in the subcoronary group) in the as-
cending aorta. Furthermore, the anchoring barbs were nec-
essary for stable deployment into the aorta.
Transvalvular Gradient and Regurgitation
Many authors have highlighted the necessity for caution in
using in vitro results to assess a valve’s performance in
vivo.8,9 Therefore the valved stents, which revealed a pres-
sure gradient of less than 7 mm Hg and a regurgitation of I°
or less in the circulatory system, were used and retested in
vivo. As the gold standard, the natural aortic valve provides
minimal obstruction to the ventricular outflow during sys-
tole. In this sense it is considered to provide maximum
forward flow efficiency. By comparison, the prosthetic or
bioprosthetic valve is more obstructive and hence less effi-
cient than the natural valve. In all our experiments, trans-
valvular pressure measurements indicated very low gradi-
ents several hours after placement of the valved stents.
Relevant stenotic transvalvular gradients were also not ob-
served in other experimental studies1,3,4 in which smaller
series of valved stents were analyzed.
Although the size of the valved stent correlated with the
width of the aorta (determined with IA-DSA) and body
weight, mild regurgitation was observed in 3 of 11 cases and
mild paravalvular leakage in 2 of 11 cases, mainly caused
by a slightly tilted stent that could not be perfectly expanded
in the ascending arched aorta. These findings demonstrate
that the valved stent effectively prevents regurgitation when
the valve has an optimal size and is anchored properly in the
descending aorta group.
In general, a suitable positioning (which might require a
slightly different stent design with the same valve design as
proposed below) and size of the valved stent leads to un-
obstructed forward blood flow and prompt opening and
closure. Therefore more experience is required with the
angiographic sizing used in this study and also with echo-
cardiographic sizing for subsequent insertion of valved
stents. Furthermore, one can postulate that the dynamic
interaction between the valved stent and aorta (which
changes its size during the cardiac cycle) could be another
reason for the mild regurgitation observed in these 3 ani-
mals, as opposed to the in vitro data of these same 3 valves,
which were collected in a rigid system.9
Stent Design
In 1992, Dake and coworkers10 started implantations of
stent graft prostheses in patients with thoracic aneurysms.
Since then, improvements in interventional catheterization
and stent technology have made percutaneous stent place-
ment a routine procedure, and more than 20 noncovered and
covered stent designs have been developed to fit the multi-
ple cardiovascular indications.11 Therefore experience with
this kind of introducer system and different stent assemblies
has been already acquired in other applications.
Limitations of the Study
Continuous electrocardiographic, hemodynamic, and pulse
oximetric monitoring was used throughout the procedure.
Nevertheless, hemodynamic parameters and global cardiac
function should be analyzed in detail in further studies (eg,
to describe the changes during implantation and deployment
of valved stents). Changes of the coronary blood flow after
supracoronary valved stent implantation should be included
in subsequent studies. Unfortunately, this has also not been
performed in other studies.1-4 Because of the echo-dense
structure of the stent, echocardiographic assessment could
not adequately be performed in all cases.
Because of the unfeasibility of the aortic valved stent
implantation into the aortic anulus, the valve had been
evaluated in the subcoronary and supracoronary position.
This experimental positioning of the valved stent was only
used because native porcine leaflets were not removed in
this study and will therefore occlude coronary ostia. As
Andersen and colleagues1 already showed in their porcine
model, the implantation of a valved stent into the annular
position is impossible because of the restriction of coronary
blood flow.
In contrast, Pavcnik and colleagues2 experimentally
showed that transannular placement of a prosthetic caged-
ball aortic valve in mongrel dogs is feasible. Their ring
assembly was successfully placed below the ostia of coro-
nary arteries and was securely anchored against the anulus
of the aorta by the barbs, and no damage to the surrounding
structures was macroscopically noted.
The degeneration of bioprosthetic valves has been
widely studied in recent years. Various causative factors are
involved that influence the durability of the valve to differ-
ent degrees.12 Because only acute studies were performed,
the long-term durability of this kind of aortic valved stent is
unknown. Questions regarding thrombogenicity, neointi-
malization, calcification, stability of position, histomorpho-
logic examination, and function during long-term follow-up
should be addressed. Percutaneous implantation is one of
several steps toward an ideal percutaneous aortic valve
replacement (ie, in human subjects with a calcified stenotic
aortic valve). Development of various techniques for imple-
menting this replacement should be also considered. Percu-
taneous aortic valve ablation techniques for aortic stenosis,
a stable scaffold enabling those intra-aortic procedures,
filters avoiding systemic embolization, and circulatory sup-
port during percutaneous aortic valve ablation and implan-
tation with a femoro-femoral bypass and left ventricular
venting should be developed. In our short-term study the
duration of deployment was about 2 minutes. Nevertheless,
a longer operation time (3 minutes) in the ascending aorta
will be necessary for percutaneous aortic valve ablation and
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implantation, and therefore hemodynamic instability can be
expected. More complex procedures at the native aortic
valve using ablation techniques should only be performed
with a circulatory support.
Future techniques will allow transluminal aortic valve
ablation, which will be the biggest challenge of this ap-
proach. Different ablation devices have to be tested to
achieve this. Preliminary in vitro studies of our laboratory
demonstrated the possibility of ablating human calcified
aortic valves with 3 different types of lasers (CO2, Hol:
YAG, and Erb:YAG lasers). Complete ablation of each
aortic cusp took 2.5 hours with the CO2 laser and 1 hour
with the Hol:YAG laser. The erbium laser was checked for
the excision of a cusp. This also took 1 hour (unpublished
data). In subsequent studies ablation time will be reduced by
optimizing the laser parameters. Examination of the remain-
ing debris solution of the lasered aortic cusps indicated
debris particles with a size between 4 m and 1 mm.
Therefore these particles have to be eliminated by using a
filter system, which has not yet been developed.
Although a great deal of work remains to be done, these
preliminary results indicate that the development of a pros-
thetic aortic valved stent for transluminal placement is fea-
sible.1-5 Probably this valved stent would be applicable to
aortic insufficiency caused by valves that are pliable enough
to be displaced against the aortic wall in the subcoronary
region but do not adequately conform to it. In patients with
fulminant endocarditis and aortic insufficiency, the valved
stent might be implanted in the descending aorta for hemo-
dynamic stabilization. Another possibility will be the im-
plantation of a valved stent into the pulmonary position,
which has already been shown by Bonhoeffer and col-
leagues.4
An ideal aortic valved stent may be achieved for long-
term use by individually lining the entire aortic root (in-
cluding the sinus), ascending aorta, and aortic arch with
stent material (including a bioprosthesis) to avoid any shift
caused by shear stress, with individually designed marked
wholes for the coronary and supra-aortic arteries. An addi-
tional anchoring of stents into the supra-aortic vessels and
the ascending valved stent should be considered.
Conclusion
The short-term effectiveness of transluminal aortic valve
implantation to the descending and ascending aorta was
evaluated and demonstrated good preliminary results in
anesthetized pigs. The future opportunity to implant aortic
valves percutaneously in human subjects will be dependent
on the development of a transluminal ablation technique
with a very low debris rate, a good filtration method avoid-
ing emboli, and an adequate circulatory support system.
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Discussion
Dr Alain F. Carpentier (Paris, France). Of course, this is a
very appealing approach, and I congratulate you for the effort you
made to develop stentless, minimally invasive valve implantation.
However, if you think about the indications and knowing what we
know in cardiac surgery, I think we could say that this technique,
if it works one day, will be particularly indicated in elderly patients
with calcified aortic stenosis. And as surgeons, we know that these
calcified lesions are extremely difficult to remove without frag-
mentation and without leaving some pieces of calcium, which
could migrate. Now, you mention this problem, but you did not tell
us what solutions you foresee to solve and prevent embolization,
which is key for the success of this operation.
A second aspect is this: We also know from clinical practice,
that if you leave even a small peripheral leak, it has some very
often important deleterious effect, even a rather small leak, either
hemolysis or insufficiency. Knowing that you will never be able to
remove all the calcium formation, then you have a high risk of
having peripheral leak. How can you solve that problem?
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Dr Lutter. Thank you very much for your kind remarks, Dr
Carpentier.
With respect to your first remark, to ablate the calcified, ste-
notic aortic valve will be a challenge, and this has been a big
problem up to now. We have performed several pilot ablation
studies and can say that different lasers can microscopically ablate
the aortic valve, but we have not had techniques up to now that
can, in the ascending aorta, ablate the calcified valve.
So you are right also with your second remark regarding the
small leaks and the possible upcoming insufficiency if you perform
a valve stent implantation in a calcified anulus. And you have to be
sure that every particle, every embolus that might come up to the
supra-aortic vessels, you have to filter, and this is truly a lot of
work to be done. Therefore, we think that, as surgeons, we should
start with this work; otherwise the cardiologists will start with this
problem. Therefore, we think we have to have a scaffold in the
ascending aorta, with which we can properly work.
Dr Hani Shennib (Montreal, Quebec, Canada). Dr Lutter,
is this technology good or bad for surgeons? Could you see that
this will ultimately be an interventional cardiology type of
technique?
And also, when you propose that a femoro-femoral bypass
would be a way to support the heart, is there a possibility of
looking at coupling this with drugs, such as adenosine, to arrest the
heart or to control hypertension?
And the other part of the question is that when you solve the
problem, you create another problem. Is embolization control an
issue here, and would you couple this with other technologies,
such as protection catheters?
Dr Lutter. Regarding your first remark, is it bad or not for
surgeons, this is a question for the future, and I cannot answer it
now. So whether you can do it on a beating heart or not, that will
be seen in the future.
And with respect to your second remark, regarding emboliza-
tion control, we do not have it right now because if you have a total
and very good filter in your ascending aorta, up to now, you have
such resistance in the ascending aorta, which you cannot have on
a beating heart.
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